Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the immunisation safeguards vulnerable infants

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”

The pregnancy vaccine operates by stimulating the mother’s body’s defences to generate protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the moment of birth, exactly when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence indicating that a two-week gap is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst noting that protection remains possible even if administered later in the third trimester.

• Nearly 85 per cent protection when vaccinated 4 weeks before birth
• Antibodies from the mother transferred through the placenta safeguard newborns from birth
• Protection achievable with 2-week gap before premature birth
• Vaccination in the third trimester still offers meaningful infant protection

Compelling evidence from the latest research

The effectiveness of the pregnancy RSV vaccine has been established through a comprehensive study carried out throughout England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately nine out of ten of all births during that six-month timeframe, providing comprehensive and reliable data of the vaccine’s practical effectiveness. The study’s results have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The scale of this research provides healthcare professionals and prospective parents with assurance in the vaccine’s proven efficacy across different groups and contexts.

The results paint a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the vast majority being infants whose mothers did not receive the vaccination. This stark contrast emphasises the vaccine’s essential role in protecting against serious illness in newborns. The drop in hospital admissions above 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.

Study design and parameters

The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospitalisations. The sizeable sample and comprehensive nature of the data gathering ensured that findings were statistically significant and reflective of the wider population, rather than isolated cases or limited subgroups.

The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology captured practical outcomes rather than laboratory-based settings, providing practical evidence of how the vaccine functions when given across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.

Understanding RSV and its dangers

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.

The infection causes deep inflammation in the lungs and airways, making it perilously hard for affected infants to breathe and feed properly. Parents commonly see their babies visibly struggling, their chests rising whilst they try to pull adequate oxygen into their compromised lungs. Whilst most infants recover with clinical support, a modest yet notable number die from RSV complications annually, making vaccination as prevention a critical public health objective for safeguarding the youngest and most vulnerable individuals in the population.

• RSV causes inflammation in lungs, resulting in severe breathing difficulties in infants
• Half of all infants catch the infection in their first few months of life
• Symptoms span from mild colds to serious chest infections that threaten life needing hospital treatment
• More than 20,000 UK infants need serious hospital treatment for RSV each year
• Few infants die from RSV complications annually in the UK

Adoption rates and expert recommendations

Since the RSV vaccine programme began in 2024, health officials have highlighted the importance of pregnant women receiving their jab at the ideal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing matters greatly for ensuring newborns receive the most robust immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery offers approximately 85% protection, experts recommend women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to maximise the antibodies transferred to their babies via the placenta.

The communication from public health bodies stays clear: pregnant women ought to prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured pregnant women that protection remains still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those delivering slightly early. This flexible approach recognises the realities of pregnancy and childbirth whilst ensuring strong protection for vulnerable newborns during their most critical early months when RSV represents the highest danger of serious illness.

Regional disparities in vaccination

Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others continue working to increase awareness and access to the jab. These geographical variations demonstrate differences across medical facilities, communication strategies, and local engagement efforts, though the national data shows consistently strong protection regardless of geographical location.

• NHS trusts launching varied communication campaigns to engage with women during pregnancy
• Geographic variations in vaccine uptake rates throughout England demand focused enhancement
• Local healthcare systems adapting programmes to align with specific population needs

Practical implications and parent viewpoints

The vaccine’s remarkable effectiveness provides tangible benefits for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the introduction of this preventative solution, the 80% reduction in admissions means thousands of infants shielded from severe infection. Parents no more face the troubling prospect of seeing their babies struggle for breath or struggle to eat, symptoms that define severe RSV infections. The vaccine has fundamentally shifted the terrain of neonatal respiratory health, giving expectant mothers a active means to protect their youngest infants during those vital initial period.

For families like that of Malachi, whose serious RSV infection resulted in severe brain damage, the vaccine’s availability carries significant emotional significance. His mother’s promotion of the jab underscores the life-altering consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now given protection. The knowledge that such significant complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to women in pregnancy during their late pregnancy, converting what was once an unavoidable seasonal threat into a manageable health risk.